NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
Levodopa-induced dyskinesia (LID) is a complication that occurs in many patients with Parkinson's disease. (-)-OSU6162 is a clinically tolerable dopamine stabilizer with affinity for both dopaminergic D2 receptors and serotonergic 5-HT2A receptors which has been shown to counteract LID in non-human primates. To investigate whether (-)-OSU6162 can dampen levodopa-induced abnormal involuntary movements in the unilateral 6-OHDA rat model of Parkinson's disease without impairing levodopa-induced improvement in motor functioning, female Sprague Dawley rats received complete unilateral lesioning of the medial forebrain bundle and were treated daily with levodopa/benserazide. Animals that developed dyskinetic behavior as assessed by involuntary abnormal movements following two weeks of treatment with levodopa/benserazide received either (-)-OSU6162 (30 mg/kg) or saline immediately prior to their next levodopa/benserazide dose. In a separate batch of animals, the same add-on treatment was given following three days of levodopa/benserazide administration prior to subjecting the animals to the stepping and cylinder tests. (-)-OSU6162 was found to significantly reduce levodopa-induced abnormal involuntary movements in dyskinetic rats without compromising the effect of levodopa in the stepping test. In conclusion, add-on of (-)-OSU6162 attenuates the expression of LID in the 6-OHDA rat model of Parkinson's disease without affecting the antiparkinsonian effect of levodopa.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.